Eosinophilic oesophagitis

Prescribing Notes:

• Treatment with Jorveza should only be commenced under specialist recommendation for eosinophilic oesophagitis. SMC advice restricts its use to patients who have unsuccessfully been treated with proton pump inhibitors.
• It is recommended that the licensed formulations designed specifically for oesophageal delivery (e.g. budesonide (Jorveza)) are favoured over utilising ingested inhaler formulations off-label (e.g. inhaled budesonide or fluticasone propionate). This involves metered dose inhalers (MDIs) being puffed into the mouth during end-expiration and swallowed rather than inhaled.
• See the Healthcare Improvement Scotland website for details around the use of a Steroid Emergency Card.